Novo Nordisk A/s

This study tested whether combining two medicines, cagrilintide and semaglutide, works better than either alone for controlling blood sugar in people with type 2 diabetes. 92 adults received either the combo or a single drug plus a dummy shot for about 32 weeks. The main goal was…

This study tested a new diabetes pill (semaglutide) against a dummy pill in 132 children and teens with type 2 diabetes. Participants took one tablet each morning on an empty stomach and waited 30 minutes before eating. The study lasted about 15 months and checked how well the me…

This study tested several medications, including semaglutide and cagrilintide, alone or together, to see if they could reduce liver damage and alcohol use in people with alcohol-related liver disease. About 270 adults with a history of heavy drinking took part. The goal was to me…

This study tested a new pen injector for giving the hemophilia A medicine Mim8. The goal was to see if the pen injector delivers the same amount of medicine into the blood as a standard syringe. 205 healthy men received one dose of Mim8 either with the pen or a syringe. The resul…

This study followed 291 adults with type 2 diabetes whose blood sugar was not well controlled on their current medication (DPP4i). Participants switched to an oral medication called semaglutide and were monitored for about 5-6 months. Researchers measured changes in blood sugar l…

This study looked at how well the diabetes pill Rybelsus (oral semaglutide) works in real-world settings for adults with type 2 diabetes. Researchers tracked changes in blood sugar levels and body weight over about 8-10 months. Participants took the medication as prescribed by th…

This study tested a new insulin that is injected just once a week against a standard daily insulin in 582 adults with type 2 diabetes. The goal was to see if the weekly insulin controls blood sugar as well as the daily one. Participants also used mealtime insulin. The trial laste…

This study tested a new once-weekly insulin (icodec) combined with a flash glucose monitor (a small sensor worn on the arm) in 51 adults with type 2 diabetes who had never used insulin before. The goal was to see if this approach helps control blood sugar levels over 26 weeks. Pa…

This study followed 155 adults with type 2 diabetes who were prescribed Rybelsus (oral semaglutide) by their doctors. The goal was to see how well the once-daily pill lowers blood sugar and affects body weight over 8-10 months. Participants completed a questionnaire about how the…

This study tested a new investigational medicine called CagriSema (a combination of two drugs) in 274 adults with type 2 diabetes who were already taking daily insulin. Participants received either CagriSema or a placebo shot once a week for about a year. The goal was to see if C…

This study tested a medicine called nonacog beta pegol (N9-GP) in 30 Chinese men aged 12-70 with moderate to severe hemophilia B. The medicine is injected into a vein to treat or prevent bleeding episodes. The trial lasted about 12-16 months and checked how well the medicine stop…

This study tested a new long-acting clotting factor drug (NNC-0156-0000-0009) in 25 children with hemophilia B. The goal was to see if it safely prevents bleeding episodes. Children received regular infusions to replace the missing clotting factor. The drug helped control bleeds,…

This study tested a new medicine called dasiglucagon against the standard treatment glucagon for severe low blood sugar in Asian adults and Japanese teenagers with type 1 diabetes. The goal was to see if dasiglucagon raises blood sugar just as quickly and safely. Participants rec…

This study tested a new medicine called CagriSema, a once-weekly injection, to help people with overweight or obesity and type 2 diabetes lose weight. About 1,200 adults received either CagriSema or a placebo for around 1.5 years. The main goals were to measure weight loss and ho…

This study tested a new medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help people with overweight or obesity lose weight. About 300 adults took part, receiving either CagriSema or a dummy shot once a week for around 1½ years. The main goal…

This study tested how well semaglutide helps people with obesity lose weight compared to other approved weight loss medications. About 500 adults from three US employers took part. The goal was to see if semaglutide leads to greater weight loss and improvements in quality of life…

This study looked at the long-term safety and effectiveness of Ozempic in over 3,200 Japanese adults with type 2 diabetes. Participants took the drug as prescribed by their doctor for about 3 years. Researchers tracked side effects, blood sugar control, weight changes, and qualit…

This study looked at how well the once-daily pill Rybelsus® works for adults with type 2 diabetes in everyday life. Researchers tracked changes in blood sugar and body weight over about 8-10 months. Participants took the medication as prescribed by their doctor and filled out que…

This study tested a new medicine, somapacitan, given once a week, against the standard daily medicine Norditropin in 200 children with growth hormone deficiency. The goal was to see if the weekly shot works as well and is safe. Children received either the weekly or daily injecti…

This study tested a once-weekly injection of semaglutide (2.4 mg) in 150 Asian adults with obesity (BMI 25 or higher). Participants received either the drug or a placebo, plus lifestyle advice, for about a year. The main goal was to see how much weight they lost. Results showed t…

This study tested a new medicine, NNC0519-0130, in 299 adults with type 2 diabetes. Participants received weekly injections of different doses to see how well it lowers blood sugar and body weight. The study lasted about 40 weeks and is now complete.

This study tested a new medicine called Mim8 in 281 adults and teens with hemophilia A, including those with inhibitors. Mim8 helps replace missing clotting factor to prevent bleeding episodes. Participants received weekly or monthly injections. The goal was to see if Mim8 works …

This study tested a weekly injection of semaglutide (2.4 mg) to help people with overweight or obesity lose weight. 375 adults took part, some receiving the drug and others a placebo, along with lifestyle counseling. The main goal was to see how much weight they lost over 44 week…

This study tested whether a new investigational medicine called CagriSema (a combination of two drugs) can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and overweight or obesity. About 626 participants received either CagriSema, one of its componen…

This study tested a new weekly medicine called CagriSema, which combines two drugs (semaglutide and cagrilintide), in over 2,700 adults with type 2 diabetes. The goal was to see if the combo lowers blood sugar and body weight better than either drug alone or a placebo. Participan…

This study tested a once-daily pill called RYBELSUS® against other diabetes pills in over 1,000 adults with type 2 diabetes who were already taking metformin. The goal was to see which pill works better at lowering blood sugar over one year. Participants were randomly assigned to…

This study tested a new oral medicine called NDec in 96 adults with sickle cell disease. The goal was to see if it can safely raise hemoglobin levels and reduce painful crises. Participants took capsules twice a week for about a year, and some also continued their usual hydroxyur…

This study tested a new fast-acting insulin (faster aspart) against a standard insulin (NovoRapid) in 331 adults with type 1 or type 2 diabetes. Both insulins were taken alongside a long-acting insulin, with or without metformin. The goal was to see if the new insulin works bette…

This study tested three different doses of semaglutide (2 mg, 8 mg, and 16 mg) in 245 adults with type 2 diabetes and overweight who were already taking metformin. The main goals were to see how well each dose lowered blood sugar and body weight over 40 weeks. Participants receiv…

This study followed 465 adults with type 2 diabetes in Spain who were already prescribed Rybelsus® (oral semaglutide) by their doctor. Researchers tracked changes in blood sugar levels, body weight, and how satisfied patients were with their treatment over 8-10 months. The goal w…

This study tested a new medicine called Mim8 in 70 children aged 1-11 with hemophilia A, some of whom had inhibitors that make standard treatments less effective. Mim8 is given as a shot under the skin to help prevent bleeding episodes. The study lasted about 54-98 weeks and trac…

This study tested whether the diabetes drug semaglutide (taken as a pill) can help people with early Alzheimer's disease. About 1,840 participants received either the drug or a placebo for up to 3 years and 4 months. The main goal was to see if semaglutide slows decline in memory…

This study tested a new medicine called Mim8 for people with hemophilia A, a condition where blood doesn't clot properly. Mim8 is a shot given under the skin that helps replace the missing clotting factor. The trial included 275 people, some healthy and some with hemophilia, to s…

This early-stage study tested a new medicine (NNC0487-0111) for weight control in 36 Chinese adults with overweight or obesity. The main goal was to check the drug's safety and how it moves through the body. Participants received either the study drug or a placebo by injection, a…

This study tested a new medicine called NNC0487-0111 in 448 adults with type 2 diabetes. The goal was to see how well different doses lower blood sugar and body weight compared to a placebo. Participants received either a weekly injection, a daily pill, or a dummy treatment for a…

This study tested a new experimental medicine called CagriSema (a combination of cagrilintide and semaglutide) against the existing drug tirzepatide for weight loss in adults with obesity. About 800 participants received weekly injections under the skin for up to 1.5 years. The g…

This study looked at how a combination medicine called CagriSema affects appetite and brain activity in people who are overweight or have obesity. About 164 participants took part, some receiving the medicine and others a placebo. The goal was to understand how the drug changes f…

This study tested a weekly injection of semaglutide (2.4 mg) versus a placebo in 407 adults with obesity and knee osteoarthritis. Participants received diet and exercise advice alongside the injection. The goal was to see if the drug could reduce body weight and ease knee pain ov…

This study tested whether CagriSema, a combination of two medicines, can reduce how much people eat and their appetite. 62 adults with overweight or obesity received either CagriSema or a placebo for about 32 weeks. Researchers measured food intake and stomach emptying to see if …

This study follows people who were in the SELECT trial for an anti-obesity medication. It does not provide any new treatment—instead, participants fill out health questionnaires every 6 months for up to 10 years. The goal is to see long-term effects like heart attacks, strokes, c…

This study looked at how different levels of kidney function affect a new medicine called NNC0519-0130 for type 2 diabetes. Thirty-six adults with normal, mildly, moderately, or severely reduced kidney function received a single dose. Researchers measured the drug levels in their…

This study tested whether health data can be collected remotely from people with overweight or obesity using a smartphone app, watch, and scale. 146 adults took part for 24 weeks, and no study medicine was given. The goal was to see how well remote data collection works for weigh…

This completed study surveyed 608 heart and kidney specialists to understand their awareness and use of a blood test called hsCRP, which measures inflammation. The goal was to learn what doctors think about inflammation's role in managing atherosclerotic cardiovascular disease, c…

This study looked at how different amounts of water and delays before breakfast affect levels of a new semaglutide tablet in the blood. 121 healthy men took the tablet daily for 10 days. The goal was to find the best way to take the medicine for future use.

This early-stage study tested a single dose of the experimental drug monlunabant in 73 healthy men of normal weight, half Japanese and half Caucasian. The main goal was to check for side effects and see how the drug moves through the body. Participants were randomly assigned to r…

This study looked at how the body processes cagrilintide, a drug being developed for weight management, in people with different levels of liver function. It involved 32 adults, including those with liver impairment and healthy volunteers. The goal was to measure drug levels in t…

This study tested a new formulation of the medicine semaglutide in healthy adults. The goal was to measure how much of the drug gets into the blood with the new tablet compared to the current one. About 264 participants took different doses daily for up to 21 weeks. The study is …

This study looked at how a high-fat meal changes the amount of the experimental drug etavopivat in the blood of 16 healthy adults. Each person took a single dose of the drug after eating a fatty meal and on an empty stomach on different days. The goal was to see if food affects h…

This early-stage study tested a single injection of an experimental drug called NNC0582-0001 in 56 healthy adults. The main goal was to check safety and how the drug moves through the body, not to treat any disease. Participants were followed for about a year after the injection.

This study tested a new medicine called etavopivat, being developed for sickle cell disease, to see if it changes the heart's electrical activity. Thirty-three healthy adults received different doses of the drug, a placebo, or an approved heart medicine. The goal was to check for…

This early-stage study tested a new medicine called NNC0581-0001 in 48 adults to see if it is safe and how the body handles it. Some participants were healthy, and others had fatty liver (hepatic steatosis). Participants received either the drug or a placebo by injection under th…

This study measured how many people with heart or kidney disease have high levels of body-wide inflammation. Researchers collected medical information from 756 adults in the Middle East during a single clinic visit. No treatments or medications were given as part of this study.

This early-stage study tested a single dose of a new oral medicine called etavopivat in 24 healthy Chinese volunteers. The main goal was to see how the drug moves through and is processed by the body (pharmacokinetics) and to check its initial safety and tolerability. The results…